EDITORIAL
Published on 04 Jul 2022
Editorial: Engineered Targeted Cancer Immunotherapies
doi 10.3389/fonc.2022.953175
- 897 views
- 2 citations
- Frontiers in Oncology
- Cancer Molecular Targets and Therapeutics
- Research Topics
- Engineered Targeted Cancer Immunotherapies
Engineered Targeted Cancer Immunotherapies
48k
Total Downloads
164k
Total Views and Downloads
Submit your idea
Select the journal/section where you want your idea to be submitted:
Articles
ORIGINAL RESEARCH
Published on 27 Apr 2022
Expression of CD274 mRNA Measured by qRT-PCR Correlates With PD-L1 Immunohistochemistry in Gastric and Urothelial Carcinoma
doi 10.3389/fonc.2022.856444
- 3,065 views
- 6 citations
REVIEW
Published on 05 Apr 2022
CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy
doi 10.3389/fonc.2022.834002
- 11,537 views
- 17 citations
ORIGINAL RESEARCH
Published on 31 Mar 2022
Generation of Tumor-Specific Cytotoxic T Cells From Blood via In Vitro Expansion Using Autologous Dendritic Cells Pulsed With Neoantigen-Coupled Microbeads
doi 10.3389/fonc.2022.866763
- 3,839 views
- 3 citations
REVIEW
Published on 07 Mar 2022
Targeting BCMA to Treat Multiple Myeloma: Updates From the 2021 ASH Annual Meeting
doi 10.3389/fimmu.2022.839097
- 10,575 views
- 6 citations
MINI REVIEW
Published on 24 Feb 2022
CD19-Targeted Immunotherapies for Diffuse Large B-Cell Lymphoma
doi 10.3389/fimmu.2022.837457
- 11,015 views
- 10 citations
ORIGINAL RESEARCH
Published on 14 Feb 2022
SP1-Mediated Upregulation of circFAM126A Promotes Proliferation and Epithelial-Mesenchymal Transition of Oral Squamous Cell Carcinoma via Regulation of RAB41
doi 10.3389/fonc.2022.715534
- 1,275 views
- 7 citations
ORIGINAL RESEARCH
Published on 09 Feb 2022
Bryostatin Activates CAR T-Cell Antigen-Non-Specific Killing (CTAK), and CAR-T NK-Like Killing for Pre-B ALL, While Blocking Cytolysis of a Burkitt Lymphoma Cell Line
doi 10.3389/fimmu.2022.825364
- 9,753 views
- 6 citations
ORIGINAL RESEARCH
Published on 02 Feb 2022
Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development
doi 10.3389/fimmu.2022.773264
- 6,284 views
- 33 citations
REVIEW
Published on 27 Jan 2022
Semaphorins as Potential Immune Therapeutic Targets for Cancer
doi 10.3389/fonc.2022.793805
- 3,584 views
- 7 citations
CASE REPORT
Published on 14 Jan 2022
Tumor Flare Reaction in a Classic Hodgkin Lymphoma Patient Treated With Brentuximab Vedotin and Tislelizumab: A Case Report
doi 10.3389/fimmu.2021.756583
- 6,592 views
- 6 citations
ORIGINAL RESEARCH
Published on 11 Jan 2022
Grabbing the Bull by Both Horns: Bovine Ultralong CDR-H3 Paratopes Enable Engineering of ‘Almost Natural’ Common Light Chain Bispecific Antibodies Suitable For Effector Cell Redirection
doi 10.3389/fimmu.2021.801368
- 4,469 views
- 17 citations
Published in
Frontiers in Oncology
- Cancer Molecular Targets and Therapeutics
- Cancer Immunity and Immunotherapy
Participating Journals
Frontiers in Immunology
- 5.7 impact factor
- 9.8 citescore
Frontiers in Pharmacology
Cancer Molecular Targets and TherapeuticsOffline
- 4.4 impact factor
- 7.8 citescore
Impact
- 164kTopic views
- 114kArticle views
- 48kArticle downloads